NRAS, NRAS proto-oncogene, GTPase, 4893

N. diseases: 611; N. variants: 17
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease HPO
CUI: C0025202
Disease: melanoma
melanoma
0.700 CausalMutation disease CGI
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE (1) The underlying melanoma-driving mutations may give rise to specific dermoscopic growth patterns, (2) BRAF/NRAS mutations in early melanomas may not be as common as previously thought, and (3) patients may be predisposed to developing specific driving mutations giving rise to melanomas or nevi of similar growth patterns. 24695820 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE 23 and 26 patients were concluded to have a NRAS-mutated or a BRAF-mutated melanoma respectively. 26204954 2015
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 21107323 2010
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Melanomas without chronic sun-induced damage (Non-CSD) were more likely (P<0.01) to show BRAF mutations while NRAS mutation frequency was unbiased between melanoma subtypes. 21788131 2012
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Melanoma is a heterogenous disease and can be subclassified based on distinct clinical characteristics, histopathological features and mutation patterns within NRAS and BRAF genes. 22621697 2013
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Melanomas with NF1 mutations typically occur on chronically sun-exposed skin or in older individuals, show a high mutation burden, and are wild-type for BRAF and NRAS. 28067895 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Melanoma onset and progression are associated with a high variety of activating mutations in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) genes, but also c-KIT and PTEN. 31446019 2019
CUI: C0025202
Disease: melanoma
melanoma
0.700 AlteredExpression disease LHGDN NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. 17119447 2006
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. 17119447 2006
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. 17297468 2007
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutations have long been known to be present in a subset of melanomas and represent an elusive subgroup for targeted therapies. 21670085 2011
CUI: C0025202
Disease: melanoma
melanoma
0.700 AlteredExpression disease BEFREE NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes. 21750866 2011
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment. 22130161 2012
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE NRAS and CKIT mutant melanoma represent the next oncogene defined melanoma subsets for which initial targeted therapy approaches are being explored, with early evidence suggesting progress with MEK and CKIT inhibitors, respectively. 22661223 2012
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. 23096702 2013
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutations were most frequently detected in acral melanomas (9.3 %), followed by melanomas without chronic sun-induced damage (7.0 %) and mucosal melanomas (4.8 %), and were not detected in melanomas with chronic sun-induced damage. 23739925 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. 24802725 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE NRAS and BRAF mutational status has become mandatory to treat patients with metastatic melanomas. 26297254 2015
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutations were rare in VVMs compared with cutaneous (25.9%; P = .009) and acral (40.6%; P = .002) melanoma subtypes. 28026870 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS-mutant tumors tended to behave more aggressively particularly in early stages of the disease in this high-risk melanoma population. 28797232 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE NRAS mutated melanoma were mainly observed in chronic sun-damaged areas and had a negative prognostic value, with shorter time to progression and a high incidence of central nervous system involvement. 29187493 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE A 80 year-old man with stage IV BRAF-wild type and NRAS exon 2-mutated melanoma was treated first line by nivolumab 3mg/kg every 2 weeks. 28438383 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE A B-RAF or N-RAS mutation was found in 8 of 23 (35%) spitzoid lesions suspected for melanoma. 16096402 2005